David C. Myles has sold OLMA and made no open-market buys since Dec 2021

David C. Myles, Ph.D. is a seasoned biotechnology executive serving as Chief Discovery and Non-Clinical Development Officer at Olema Pharmaceuticals, Inc. (OLMA) since September 2022, following roles as Chief Development Officer and Executive Vice President of Drug Discovery and Development since April 2008.( Age 63, he brings over 17 years of tenure at Olema, focusing on oncology discovery, particularly ER+ breast cancer programs, with recent contributions to advancing OP-1250 into Phase 3 and other pipeline milestones achieving above-target corporate performance in 2023 (125%) and 2024 (107%).(

Myles holds a Ph.D. from Yale University (1989) and a B.A. from Occidental College, complemented by an NIH post-doctoral fellowship at Harvard.( His career highlights include co-founding Epiphany Biosciences as COO (2006–2008), leading chemistry as Executive Director at Kosan Biosciences (2001–2006), directing medicinal chemistry as Associate Director at Chiron Corporation (1998–2001), and serving as Assistant Professor at UCLA (1991–1998).( Currently, he chairs the Finance Committee at Point Blue Conservation Science and serves as a Trustee at The Webb School of California.( In January 2026, Myles sold 65,000 OLMA shares worth $2.97 million across multiple transactions.(

Written by Perplexity from public sources.